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Background The reported incidence of hepatocellular
carcinoma (HCC) among patients with primary biliary
cirrhosis (PBC) varies from 0.7–3.8%, whereas in cirrhotic
patients the risk is considerably higher. Age, male sex,
cirrhosis, and portal hypertension are reported risk factors.
It has been suggested that ursodeoxycholic acid
(UDCA) may protect against HCC. We aimed to define risk
factors for the development of HCC at the time of PBC
diagnosis and to identify, among patients treated with
UDCA for a long term, a subgroup that could benefit from
screening.
Methods Prospective multicenter cohort study of patients
with established PBC treated with 13–15 mg/kg/day
UDCA. Age, sex, antimitochondrial antibodies, bilirubin,
albumin, alkaline phosphatase, alanine aminotransferase,
aspartate amino transferase, cirrhosis, portal hypertension,
Mayo Risk Score, prognostic class (based on bilirubin and
albumin levels), and response to UDCA (normalization of
bilirubin and/or albumin levels) were analyzed as potential
risk factors in Cox regression analysis.
Results Three hundred and seventy-five patients were
included, median follow-up was 9.7 years. HCC occurred
in nine patients, corresponding with an annual incidence
of 0.2%. The factor significantly associated with the
development of HCC was the response to UDCA
(P < 0.001). The risk for HCC was highest in the group
of nonresponders to UDCA: the 10 years incidence of HCC
was 9% and the 15 years incidence was 20%. The number
needed to screen in this subgroup was 11.
Conclusion In UDCA treated PBC patients the risk of HCC
is relatively low. The main risk factor for HCC in this
study was the absence of biochemical response to UDCA
after 1-year treatment. Eur J Gastroenterol Hepatol
22:1495–1502 c 2010 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver
disease, which predominantly occurs in middle-aged women.
In patients with nonadvanced disease and who are treated
with ursodeoxycholic acid survival seems to be comparable
with the general population and causes of death are mainly
nonliver related [1]. The overall incidence of hepatocellular
carcinoma (HCC) among PBC patients varies from 0.7 to
3.8% [2,3], whereas an incidence of up to 14% has been
reported for those with cirrhotic disease (Table 1) [3].
Limited data are available on a possible protective effect of
treatment with ursodeoxycholic acid (UDCA) [8].
Several risk factors for HCC have been reported,
including histological stage, sex, age, presence of portal
hypertension, and history of blood transfusion [3,8,11].
Ideally, surveillance programs should be limited to those
patients carrying a significant risk for HCC and these
patients should be easily identifiable to prevent burden
of medical resources. In addition, tumors should be
detected at an early stage.
Today, surveillance for HCC is solely recommended for
PBC patients with cirrhosis [12]. This strategy, however,
has inherent disadvantages, the most important being the
necessity of repeated diagnostic procedures, such as liver
biopsy, in the majority of cases who present with
noncirrhotic disease. Further, liver biopsy is associated
with sampling error and interpretation difficulties.
Silveira et al. [11] developed a model to predict HCC
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based on age, sex, portal hypertension status, and history
of blood transfusions, but the criterion of portal hyper-
tension has the same disadvantages as histological status
and the model has not been validated yet.
The aim of this study was to evaluate epidemiology of
PBC related mortality focused on HCC in a large UDCA-
treated cohort. We aimed to define risk factors for the
development of HCC early in the disease process to
identify a subgroup of PBC patients who could most
likely benefit from surveillance.
Patients and methods
The Dutch Multicenter PBC Study is a multicenter
prospective cohort study of PBC patients. The primary
goal was to analyze long-term prognosis, in particular
survival and causes of death, in patients treated with
UDCA. Inclusion started in January 1990 and follow-up
data until April 2007 were analyzed [1]. A definite
diagnosis of PBC was made in the presence of two major
plus two minor criteria or one major plus four minor
criteria. Major criteria were antimitochondrial antibodies
titer greater than or equal to 1 : 20 and compatible liver
biopsy, whereas minor criteria were pruritus, jaundice,
alkaline phosphatase (ALP) greater than or equal to two-
fold the upper limit of normal (ULN), serum IgM more
than 2.8 g/l, and positive Schirmer test [13]. Available
liver biopsies were reviewed according to Ludwig et al.
[14]. Exclusion criteria were the earlier or current treat-
ment with UDCA, aged above 75 years, pregnancy,
evidence of extra hepatic biliary disease, autoimmune-
overlap syndrome or use of immunosuppressive drugs,
concomitant disorders limiting life expectancy, and de-
compensated PBC, defined as Child-Pugh class B or C
cirrhosis. Patients were eligible irrespective of the interval
between diagnosis and inclusion. After inclusion, patients
started with the UDCA therapy of 13–15 mg/kg/day [15].
Follow-up data with respect to HCC, other complica-
tions, liver transplantation (LTX), and (causes of) death
were collected at 3-month intervals in the first year and at
yearly intervals thereafter. At each visit general physical
examination and laboratory studies including bilirubin,
albumin, ALP, aspartate aminotransferase (AST), alanine
aminotransferase, albumin, immunoglobulin G, immuno-
globulin M, and total cholesterol were performed. Liver
tests were reported as the ratio of the test result to the
ULN or lower limit of normal for the laboratory test.
Information on the causes of death was retrieved from
hospital case records. In a limited number of cases, for
instance if patients were lost to follow-up, family doctors
or other hospitals were contacted.
The cohort study started well before the first consensus
guidelines on HCC screening appeared. Therefore, with
respect to screening liver imaging studies and measure-
ment of fetoprotein levels were performed according to
the policy of the individual participating hospitals.
Definitions and statistical analysis
Survival was analyzed as transplantation-free survival
(end-points: LTX and death). Liver-related death was
defined as: death because of liver failure or HCC, or
death occurring within 2 months of an episode of variceal
bleeding, spontaneous bacterial peritonitis, hepatorenal
syndrome, or hepatic encephalopathy. Patients lost to
follow-up were censored at the time of their last visit.
Survival was compared with the survival of the Dutch
population, matched for sex, age, and time of observation.
Data for the Dutch population were derived from an
official demographic database. For time-to-event analysis,
we applied the Kaplan–Meier method and compared
groups using the log-rank test.
Possible risk factors for HCC at diagnosis were evaluated
using univariate and multivariate Cox regression analysis.
We calculated the estimated risk to develop HCC based
on the Silveira model. On the basis of serum bilirubin and
albumin values the following prognostic classes were
defined: early PBC (both bilirubin and albumin normal),
moderately advanced PBC (one parameter normal), or
advanced PBC (both parameters abnormal) [16]. Further,
based on Mayo Risk Scores, the disease was classified
Table 1 Reported annual and cumulative incidences of hepatocellular carcinoma in patients with primary biliary cirrhosis
Patients Follow-up Annual incidence Cumulative incidence
Year First author Time period N UDCA Years Total (%)
Ludwig stage
III/IVa (%) Total (%)
Ludwig stage
III/IVa (%)
1994 Farinati et al. [4] 1976–1981 89 b 5.5/4.3 0.4 1.4 2.2 6.1
1997 Jones et al. [5] 1975–1995 667 b 7.3 0.3 0.8 2.4 5.9
1999 Nijhawan et al. [6] 1976–1985 1689 b 4.4 0.2 — 0.7 —
2001 Caballeria et al. [7] 1977–1996 140 b 5.6 0.6 2.0 3.6 11.1
2001 Shibuya et al. [8] 1980–1998 396 b 3.6 1.0 3.4 3.5 12.3
2002 Findor et al. [9] 1978–1998 292 b 3.0 0.5 1.1 1.3 3.4
2003 Floreani et al. [10] 1973–1999 170 b 6.2 0.5 — 3.0 —
2007 Jackson et al. [2] 1987–2002 395 Yes 3.7 0.2 — 0.7 —
2008 Deutsch et al. [3] 1987–2005 212 Partly 6.0/7.0 0.6 2.1 3.8 14.5
This study 1990–2007 375 Yes 9.7 0.2 0.2 2.4 1.9
UDCA, ursodeoxycholic acid.
aHistological stage III (marked liver fibrosis) and IV (cirrhosis).
bNo details on UDCA treatment.
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as low risk (score < 4.5) or high-risk (score Z 4.5) [17].
Portal hypertension was defined as presence of ascites
and/or a history of variceal bleeding. Biochemical
response to UDCA treatment was defined as normal
bilirubin and albumin concentrations after a 1-year
treatment with UDCA when one or both parameters
were abnormal before treatment, or as normal bilirubin or
albumin concentration after treatment when both were
abnormal at entry. Patients with persistently normal
levels were also regarded as responders to therapy [1].
The occurrence of events during follow-up, including
HCC, LTX, and death, was expressed as the cumulative
incidence (CI) and the annual incidence (AI). CI re-
presents the CI or total incidence over the complete
follow-up period, whereas AI represents the mean AI.
A P value of less than 0.05 (two-tailed) was considered
statistically significant. Statistical package SPSS 15.0




The baseline patient characteristics are summarized in
Table 2. The study population comprised 375 (89%
female) patients, with a mean age of 54.7 years, who were
followed for a median period of 9.7 (range: 1–17.3) years.
Sixteen (4%) patients were lost to follow-up. After
inclusion, the total number of study visits with collection
of laboratory and clinical data was 4776; the average
number of data collections was nine per patient. The
majority of patients (60%) suffered from early PBC. The
available liver biopsies [65% (n = 161)] were histologi-
cally classified as Ludwig stage I or II disease.
Survival
Compared with a sample of the general Dutch popula-
tion, transplantation free survival of our PBC cohort was
significantly lower (P < 0.001). Survival of the total PBC
cohort was 67%, for the standardized Dutch population
whereas the 15-years survival rate was 80%.
The incidence of nonliver related death in our cohort was
comparable to that of the general population and the
difference in survival can be explained by liver related
causes, assuming liver related death and nonliver related
death are independent events (Fig. 1).
Causes of death
During follow-up 69 out of 375 (18%) patients died and
22 (6%) underwent LTX. The number of deaths and
transplantations was 34 in patients with early PBC, 35 in
moderately advanced PBC, and 22 in advanced PBC.
Causes of death were mainly nonliver related for patients
with early PBC: in this subgroup only 18% (six out of 34)
of the patients died from liver related causes or under-
went LTX. Liver related death and LTX occurred
relatively more often in moderately advanced and
advanced PBC: 63% (22 out of 35) and 91% (20 out
of 22), respectively. The AI of liver-related death and
transplantation was 0.3, 2.4, and 8.8% for early, moder-
ately advanced, and advanced PBC, respectively
(Table 3). HCC accounted for 33% (two out of six)
of liver-related causes of death in early PBC, for 27%
(six out of 22) in moderately advanced PBC, and for 5%
(one out of 20) in advanced PBC. The corresponding AI
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Survival of the cohort of 375 patients with primary biliary cirrhosis
(PBC) compared with a matched sample of the Dutch population.
Survival of patients with PBC was clearly lower than in the general
population. The excess mortality in PBC is attributable to liver-related
causes of death (light gray area). The incidence of nonliver related
death (dark gray area) was comparable for both populations (the line
between liver related death and nonliver related death was calculated,
assuming that liver related death and nonliver related death are not
related).
Table 2 Baseline patient characteristics (n = 375)
Age (years; mean ± SD) 54.7 ± 10.9
Sex (male/female) 40 (11%)/335 (89%)
AMA + 350 (93%)
ALP (ULN, range) 2.7 (0.4–13.0)
AST (ULN, range) 1.6 (0.3–7.4)
ALT (ULN, range) 2.0 (0.3–12.1)
Bilirubin (ULN, range) 0.7 (0.1–5.6)
Albumin (LLN, range) 1.1 (0.3–7.2)
Igm (ULN, range) 1.9 (0.2–17.5)
Igg (ULN, range) 1.0 (0.1–2.9)








Early PBC 225 (60%)
Moderately advanced PBC 95 (25%)
Advanced PBC 34 (9%)
Not available 21 (6%)
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochon-
drial antibodies; AST, aspartate amino transferase; IgG, immunoglobulin G; IgM,
immunoglobulin M; LLN, lower limit of normal; PBC, primary biliary cirrhosis; SD,
standard deviation; ULN, upper limit of normal.
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Hepatocellular carcinoma cases
During follow-up nine cases of HCC were diagnosed
(Table 4). Seven of these patients were female, the mean
age at the diagnosis of PBC was 57 ± 9 years, and at the
HCC diagnosis of 66 ± 11 years. At HCC diagnosis 33%
(three out of nine) of the patients were aged above 70
years. The time from PBC diagnosis to the development of
HCC was 16 ± 5 [mean ± standard deviation (SD)] years.
Diagnosis was made by the characteristic findings on MRI
or computed tomography imaging in combination with
markedly elevated (and rising) a-fetoprotein levels. Four
out of the nine cases with HCC diagnosis were confirmed
by histology of needle biopsies (n = 2), surgical explant
specimen (n = 1), or autopsy material (n = 1).
At PBC diagnosis the Mayo Risk Score was greater than or
equal to 4.5 in 78% of the patients, at HCC diagnosis this
was 100%. Initially, liver histology showed Ludwig stage III
or IV in four out of seven cases, but at the time of HCC
diagnosis all nine patients had progressed to stage III or IV.
Three patients were diagnosed with multifocal HCC. The
mean diameter of the largest tumor was 42 ± 28 mm (SD).
At the time of HCC diagnosis a-fetoprotein levels were
elevated in all cases, varying from three to 112 times the
ULN.
Table 3 Causes of death in a cohort of 375 ursodeoxycholic acid-treated primary biliary cirrhosis patients
Early PBC (n = 225) Moderately advanced PBC (n = 95) Advanced PBC (n = 34)
Age at entry (years; mean ± SD) 54 ± 11 55 ± 11 57 ± 10
Follow-up (months; mean ± SD) 124 ± 50 118 ± 55 80 ± 56
Liver related death/transplantation (n) (AI) 6 (0.3) 22 (2.4) 20 (8.8)
Liver failure 4 (0.2) 16 (1.7) 20 (8.8)a
HCC 2 (0.1) 6 (0.6) —
Nonliver related death (n) (AI) 28 (1.2) 13 (1.4) 2 (0.9)
Cardio-respiratory disease 11 (0.5) 2 (0.2) 1 (0.4)
Cerebrovascular accident 3 (0.1) 4 (0.4) —
Nonhepatic malignancy 8 (0.3) 1 (0.1) —
Other causes 6 (0.3) 6 (0.6) 1 (0.4)
Alive at end of study (n) 180 56 11
Age at the time of death (years; mean ± SD) 72 (9) 63 (13) 65 (10)
HCC was detected in autopsy material.
AI, annual incidence; HCC, hepatocellular carcinoma; PBC, primary biliary cirrhosis; SD, standard deviation.
aOne patient died from liver failure.
Table 4 Details of nine patients with primary biliary cirrhosis who developed hepatocellular carcinoma
Case 1 2 3 4 5 6 7 8 9 Total
Female sex No No Yes Yes Yes Yes Yes Yes Yes 78%
Age at diagnosis PBC (years) 56 57 42 47 48 62 58 37 39 50 ± 9
Age at diagnosis HCC (years) 76 68 50 66 63 78 78 50 60 66 ± 11
Interval diagnosis PBC–HCC (years) 20 11 7 19 14 16 20 13 21 16 ± 5
Mayo Risk Score
At diagnosis of PBC 4.6 4.8 5.6 3.7 6.1 4.9 5.2 4.6 4.4 4.9 ± 0.7
At diagnosis of HCC — 5.5 5.7 4.9 9.8 9.0 8.0 — 5.8 7.0 ± 5.8
Histological stage PBC 3.4 ± 1.3
At diagnosis PBC — III III II III NA II II IV
At diagnosis HCC IV III IV IV IV III IV IV IV 3.8 ± 0.4
Portal hypertension No Yes Yes Yes Yes Yes Yes NA Yes 88%
History blood transfusion No Yes No No No No No NA No 13%
Body mass index 22 27 22 25 19 30 26 30 22 25 ± 4
Other liver disease No No No No No Yesa No No No 11%
Nodules 2 1 1 2 1 1 2 1 1 1.3 ± 0.5
Diameter (mm)b 80 — 5 37 24 25 68 75 25 42 ± 28
AFP levels (ULN)
At diagnosis PBC — 0.2 0.6 — 0.8 — 0.7 — 0.7 0.6 ± 0.2
At diagnosis HCC 55.6 56.7 12.9 112.1 11.2 3.3 23.1 NA 72.3 42 ± 40
Predicted risk for HCC (%)c 5.9 46.7 5.6 15.6 15.6 64.8 64.8 — 15.6 28 ± 24
Prognostic classd
At diagnosis PBC 2 1 3 1 2 2 2 2 2 1.9 ± 0.6
At diagnosis HCC 3 3 3 NA 3 3 3 NA 3 3
Responder to UDCA No Yes No Yes No No No No No 22%
Treatment None None LTX RFA None None None None PEI —
Status Dead Dead Alive Dead Dead Dead Dead Dead Dead —
Survival (months) 10 14 133 23 0 1 35 23 9 13 ± 12
AFP, a-fetoprotein; HCC, hepatocellular carcinoma; LTX, liver transplantation; NA, not available; PBC, primary biliary cirrhosis; PEI, percutaneous ethanol injection; RFA,
radio frequency ablation; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
aEarlier hepatitis B, HBsag negative.
bOf the largest tumour nodule.
cAccording to Silveira et al. [11].
d1 = early PBC, 2 = moderately advanced PBC, 3 = advanced PBC.
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The mean predicted probability to develop HCC
according to the Silveira model, based on sex, age,
presence of portal hypertension, and history of blood
transfusion, was 28 ± 24% (SD) [11].
According to pretreatment bilirubin and albumin levels,
seven out of the nine HCC cases were categorized as
moderately advanced or advanced PBC at diagnosis
(78%). All seven patients were nonresponders to treat-
ment with UDCA, based on Rotterdam criteria.
According to the Paris [18] and Barcelona [19] criteria for
response to UDCA treatment, one out of nine (11%) and
six out of nine (67%), respectively, of our PBC patients
with HCC were nonresponders. However, the two
patients not responding according to the Rotterdam
criteria were responders according to the Barcelona
criteria. Thus, responders identified by one set of criteria
are not identical to responders when other criteria are
used, and the way biochemical response is defined is
obviously of major importance when interpreting the
results of this and comparable studies.
All but one patient died within 3 years of HCC diagnosis.
One patient underwent liver transplantation and was
alive for 133 months.
Risk factors hepatocellular carcinoma
To determine the risk factors for the development of
HCC, univariate analysis was performed concerning the
following baseline variables: age, sex, antimitochondrial
antibodies, total serum bilirubin, serum albumin, ALP,
alanine aminotransferase, AST, the presence or absence of
cirrhosis and portal hypertension, Mayo Risk Score, and
prognostic class (early/moderately advanced/advanced
PBC). Bilirubin (P = 0.001), AST (P = 0.003), prognostic
class (P = 0.017), and Mayo Risk Score (P = 0.004) were
significantly associated factors. In multivariate analysis no
factor remained statistically significant.
In univariate analysis, at 1 year after diagnosis, response
to UDCA was significantly associated with the develop-
ment of HCC (P = 0.001).
In the total population the AI of HCC was 0.2% and the
CI was 2.4% (nine out of 375) (Fig. 2a). The incidence of
HCC was comparable for men and women (P = 0.32), for
Ludwig stage I/II and III/IV (P = 0.98) and for the
presence and absence of portal hypertension (P = 0.112).
Mayo Risk Scores greater than or equal to 4.5 and
moderately advanced PBC were significant risk factors for
HCC (Fig. 2e and f). The highest incidence of HCC was
found in patients who were nonresponders to UDCA
treatment (Fig. 2g).
The AI of HCC in patients with cirrhosis (n = 86) was
0.2%, in patients with Mayo Risk Scores greater than or
equal to 4.5 was (n = 96) 1%, in patients with moderately
advanced PBC was (n = 95) 0.7%, and in patients not
responding to UDCA was 1.4%. In patients with
moderately advanced disease who failed to respond to
UDCA (n = 48), the annual risk was 1.5%.
In 78% of HCC cases the Mayo Risk Score was greater
than or equal to 4.5. Hypothetically, when this criterion
would have been used for initiating a screening program,
and assuming 100% sensitivity of the program, the
number needed to screen (NNS) to identify one case
with HCC would have been 14. Similarly, the NNS in
moderately advanced PBC cases would have been 16, in
UDCA nonresponders 11, and in moderately advanced
PBC and UDCA nonresponse eight.
Discussion
This cohort study consisting of 375 UDCA treated PBC
patients found a total incidence of HCC of 2.4% after a
median follow-up of 9.7 years. The AI of HCC was 0.2%
and this is the lowest reported risk of HCC in PBC.
However, a comparable incidence of HCC in PBC was
found by two other studies [2,6]. Nineteen percent of
liver related death was secondary to HCC and this was
responsible for 30% of liver related mortality in patients
with early or moderately advanced PBC. Thus, although
the absolute number of cases with HCC was only nine,
HCC was a significant cause of death secondary to liver
disease. The most important risk factor for future develop-
ment of HCC in this study was the nonresponse to UDCA
treatment, which was noted in seven out of the nine HCC
cases. In the subgroup of patients not responding to UDCA
the incidence of HCC was 9% after 10 years and 20% after
15 years. The a posteriori calculated NNS to identify a case
of HCC in this population was 11. In the group of patients
with advanced PBC only one case with HCC was observed,
this was an incidental finding at autopsy of patients who
died from liver failure. The low incidence of HCC in this
subgroup might be explained by the severity of the disease
leading to liver-related death and liver transplantation
preceding potential development of HCC.
Although this study included a relatively large population
followed prospectively during a substantial time period, the
absolute number of HCC cases was low. Therefore, the
results should be interpreted cautiously, and our finding
that nonresponse to UDCA is a main risk factor for HCC
awaits confirmation by other studies. In this study the
screening strategy was left to the individual participating
centers. In theory a uniform, standardized program could
have been more effective in identifying cases with HCC. It
seems unlikely, however, that this would have resulted in
identifying substantially more cases, given the strong
association between HCC and clinical symptoms, albeit
at variable points in time of its natural history.
This study did not confirm the major prognostic
importance of cirrhosis for future HCC. It should be
noted, however, that histological staging at entry was
possible in only two-thirds of the population. Possibly this
PBC and the incidence of HCC Kuiper et al. 1499
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Kaplan–Meier plots showing the cumulative incidence of hepatocellular carcinoma in the total group of patients with primary biliary cirrhosis (PBC)
(a) and in subgroups of patients according to sex (b), histological stage (c), presence of portal hypertension (d), Mayo Risk Score (MRS) (e),
prognostic class at the time of PBC diagnosis (f), response to ursodeoxycholic acid (UDCA) after 1-year of treatment (g) and the combination of
moderately advanced PBC and response to UDCA (h). The number of patients at risk is shown under the x-axis.
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may have resulted in lack of power for cirrhosis in the
multivariate Cox regression analysis. Therefore, the
results of this study should not be interpreted as
providing proof for cirrhosis not being a major risk factor
for HCC.
A potential major advantage of using nonresponse to
UDCA for selecting patients for screening procedures for
HCC is that such patients can be recognized early, that
is after 1-year treatment with UDCA. In addition, the
necessary data are easily available and do not require
particular (invasive) diagnostic procedures such as liver
biopsy or gastrointestinal endoscopy. We have found
earlier that nonresponders in comparison with responders
had higher pretreatment serum levels of bilirubin, ALP,
AST, higher Mayo Risk Scores, and histologically more
advanced disease. Survival for nonresponders was sig-
nificantly worse than for responders [1]. Hypothetically,
ongoing inflammatory activity and cholestasis super-
imposed on significant liver fibrosis or cirrhosis are the
most important drivers of carcinogenesis in UDCA
nonresponsive patients. For the time being, however, it
remains speculative as to which biological mechanism
could explain the high cancer risk in UDCA nonrespon-
ders, also considering the significantly lower or lacking
prognostic significance of cirrhosis, portal hypertension,
and Mayo Risk Score.
Two out of the nine patients developing HCC were
responders to UDCA. Both patients had biochemically
nonadvanced disease at entry, as reflected by normal
serum bilirubin and albumin levels. We were unable to
identify particular factors posing these patients at an
increased risk for HCC.
Obviously, further studies are required to confirm the
prognostic significance of nonresponse to UDCA according
to our criteria and to determine whether nonresponse
according to other, in particular the Barcelona [19], criteria
is a risk factor for HCC.
We could not confirm the usefulness of the Silveira risk
model for HCC [20]. This model was developed using a
case–control design and found that older age, male sex,
history of blood transfusion, and any sign of portal
hypertension indicated a high risk of HCC. Our patients
with HCC were comparable with the Mayo clinic patients
at the time of HCC diagnosis with respect to age, BMI,
alcohol consumption, histological stage at PBC diagnosis,
presence of portal hypertension, and Mayo Risk Score.
However, the duration from PBC diagnosis until the
development of HCC was significantly longer in our
population compared with the Mayo clinic patients
(93 ± 13 vs. 192 ± 60 months), the proportion of male
patients was lower (41 vs. 22%), and our patients often
received less blood transfusions (59 vs. 13%). Possible
explanations for these diverging results are a retro-
spective versus a prospective study design, geographical
differences, and a potential protective or delaying effect
of UDCA in the development of HCC. A protective effect
of UDCA was also suggested by Jackson et al. [2] who
reported a three-fold increased risk for HCC in treated
PBC patients versus an eight-fold increased risk in un-
treated patients in comparison with the general population.
Another study including treated and nontreated patients
found that UDCA was not independently associated with
the development of HCC [3].
According to the American Association for the Study of
Liver Diseases and the European Association for the
Study of the Liver practice guidelines surveillance
programs in patients with cirrhosis should be considered
when the risk of HCC is at least 1.5% per year [12,21].
The American Association for the Study of Liver Diseases
guideline proposed screening in PBC patients with
cirrhosis based on earlier findings of a risk for HCC that
was comparable with that in hepatitis C cirrhosis [7]. We
found an AI of HCC in individuals with cirrhosis of only
0.2% and this would clearly argue against screening in this
population. Several other studies also reported a risk for
HCC lower than 1.5% per year in patients with advanced
histological stages [4,9,5]. In our study the only population
carrying the proposed minimal 1.5% annual risk for HCC
was the group of patients with moderately advanced PBC
who failed to respond to UDCA. However, three out of our
nine HCC cases would not have been selected for
screening according to these criteria. A slightly lower
annual HCC risk of 1.4% was established for patients not
responding to UDCA. Our data, therefore, suggest that the
population most likely to benefit from screening would be
patients who fail to respond to UDCA.
In conclusion, this multicenter prospective study found
a relatively low risk for HCC in patients who were all
treated with UDCA for a long-term. We could not confirm
the prognostic importance of male sex, cirrhosis, portal
hypertension, and a history of blood transfusion. The
strongest risk factor for HCC in our population was the
absence of biochemical response after 1-year treatment
with UDCA. In this subgroup the 15-year incidence of
HCC was 20% and the NNS was 11.
Further studies are required to confirm that the simple
criterion of nonresponse to UDCA treatment is superior
to cirrhosis as the criterion for selecting individuals with
PBC for screening programs.
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